Add-on Acquisition • Renewable Energy

Telix Pharmaceuticals Acquires QSAM Biosciences

On February 8, 2024, Telix Pharmaceuticals acquired renewable energy company QSAM Biosciences

Acquisition Context

This is Telix Pharmaceuticals’ 1st transaction in the Renewable Energy sector.
This is Telix Pharmaceuticals’ 2nd transaction in the United States.
This is Telix Pharmaceuticals’ 1st transaction in Texas.

Explore All 407 Add-on Acquisition Renewable Energy Deals - Search the Database Free

M&A Deal Summary
Date	February 8, 2024
Target	QSAM Biosciences
Sector	Renewable Energy
Buyer(s)	Telix Pharmaceuticals
Deal Type	Add-on Acquisition

Target Company

QSAM Biosciences

Austin, Texas, United States

QSAM Biosciences is a provider of waste management services for small-scale waste water treatment plants and other producers of methane and organic waste. Its current pilot staged combined heat and power (CHP) technology can be deployed with minimal time and expense at thousands of small-scale facilities that must dispose of waste such as methane, biogas and other used fuels at increasingly greater costs and regulatory burdens. QSAM Biosciences was founded in 2004 and is based in Austin, Texas.

Explore More Deals

Browse All 215,158 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Buyer Overview 1

Buyer

Telix Pharmaceuticals

North Melbourne, Australia

Category	Company
Sector	Life Science

DESCRIPTION

Telix Pharmaceuticals Ltd. is a clinical-stage biopharamaceutical company headquartered in Melbourne, Australia. Telix is developing an advanced portfolio of clinical-stage products that address significant unmet medical need in oncology, particularly renal, prostate and brain (glioblastoma) cancer.

Deal Context for Buyer	#
Overall	3 of 7
Sector: Renewable Energy	1 of 1
Type: Add-on Acquisition	1 of 4
State: Texas	1 of 2
Country: United States	2 of 5
Year: 2024	1 of 4

PREVIOUS DEAL

DATE	TARGET	DEAL TYPE	VALUE
2022-11-14	Optimal Tracers Sacramento, California, United States Optimal Tracers is a radiochemistry development business providing radiochemistry process development services and research tracers for use in clinical trials. Optimal Tracers is based in Sacramento, California.	Buy	-

DATE

TARGET

DEAL TYPE

VALUE

2022-11-14

Optimal Tracers

Sacramento, California, United States

Optimal Tracers is a radiochemistry development business providing radiochemistry process development services and research tracers for use in clinical trials. Optimal Tracers is based in Sacramento, California.

Buy

FOLLOWING DEAL

DATE	TARGET	DEAL TYPE	VALUE
2024-02-27	IsoTherapeutics Angleton, Texas, United States IsoTherapeutics is a privately held, commercial-stage company, which provides radiochemistry and bioconjugation development and contract manufacturing services. IsoTherapeutics was founded in 2005 and is based in Angleton, Texas.	Buy	-

DATE

TARGET

DEAL TYPE

VALUE

2024-02-27

IsoTherapeutics

Angleton, Texas, United States

IsoTherapeutics is a privately held, commercial-stage company, which provides radiochemistry and bioconjugation development and contract manufacturing services. IsoTherapeutics was founded in 2005 and is based in Angleton, Texas.

Buy

Explore Related M&A Activity

Renewable Energy M&A - Add-on Acquisition M&A Deals - Texas M&A - United States M&A - 2024 M&A